Richard Wray

1.2k total citations
36 papers, 929 citations indexed

About

Richard Wray is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Richard Wray has authored 36 papers receiving a total of 929 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Cardiology and Cardiovascular Medicine, 18 papers in Surgery and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Richard Wray's work include Lipoproteins and Cardiovascular Health (12 papers), Venous Thromboembolism Diagnosis and Management (5 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (5 papers). Richard Wray is often cited by papers focused on Lipoproteins and Cardiovascular Health (12 papers), Venous Thromboembolism Diagnosis and Management (5 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (5 papers). Richard Wray collaborates with scholars based in United Kingdom, United States and Australia. Richard Wray's co-authors include B. Maurer, Anthony S. Wierzbicki, J. P. Shillingford, Dimitri P. Mikhailidis, Christopher D. Byrne, Martin Crook, Robert Cramb, William G. Simpson, John Shillingford and Treena Cranston and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Communications.

In The Last Decade

Richard Wray

34 papers receiving 837 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Richard Wray United Kingdom 16 467 245 224 112 91 36 929
Per‐Ola Attman Sweden 21 462 1.0× 199 0.8× 382 1.7× 36 0.3× 80 0.9× 44 1.3k
Irena Keber Slovenia 21 228 0.5× 692 2.8× 317 1.4× 47 0.4× 159 1.7× 59 1.3k
Tomasz Fabiszak Poland 20 393 0.8× 629 2.6× 189 0.8× 83 0.7× 67 0.7× 61 1.2k
Gerd Assmann Germany 7 447 1.0× 275 1.1× 472 2.1× 26 0.2× 145 1.6× 8 888
Susan R. Heckbert United States 14 201 0.4× 422 1.7× 127 0.6× 215 1.9× 166 1.8× 24 946
Gursharan Dogra Australia 22 291 0.6× 330 1.3× 228 1.0× 38 0.3× 157 1.7× 42 1.4k
Aldona Kubica Poland 23 438 0.9× 769 3.1× 210 0.9× 93 0.8× 82 0.9× 110 1.6k
Robert Clarke United Kingdom 13 377 0.8× 339 1.4× 216 1.0× 23 0.2× 186 2.0× 22 1.3k
H Wilkes United Kingdom 13 197 0.4× 359 1.5× 251 1.1× 172 1.5× 176 1.9× 16 1.3k
Chen Shapira Israel 15 236 0.5× 198 0.8× 172 0.8× 39 0.3× 83 0.9× 26 978

Countries citing papers authored by Richard Wray

Since Specialization
Citations

This map shows the geographic impact of Richard Wray's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Wray with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Wray more than expected).

Fields of papers citing papers by Richard Wray

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Wray. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Wray. The network helps show where Richard Wray may publish in the future.

Co-authorship network of co-authors of Richard Wray

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Wray. A scholar is included among the top collaborators of Richard Wray based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Wray. Richard Wray is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wray, Richard, Ferdia A. Gallagher, Iosif Mendichovszky, et al.. (2025). Angiogenic and immune predictors of neoadjuvant axitinib response in renal cell carcinoma with venous tumour thrombus. Nature Communications. 16(1). 3870–3870. 1 indexed citations
2.
Wierzbicki, Anthony S., et al.. (2010). The effect of fibrate–statin combination therapy on cardiovascular events: a retrospective cohort analysis. Current Medical Research and Opinion. 26(9). 2141–2146. 9 indexed citations
3.
Wray, Richard, et al.. (2005). Hypertriglyceridaemia and malignancy. International Journal of Clinical Practice. 59(2). 253–255. 2 indexed citations
4.
Humphries, Steve E., Treena Cranston, Marcus Allen, et al.. (2005). Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolaemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing. Journal of Molecular Medicine. 84(3). 203–214. 56 indexed citations
5.
Marteau, Theresa M., Victoria Senior, Steve E. Humphries, et al.. (2004). Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: A randomized controlled trial. American Journal of Medical Genetics Part A. 128A(3). 285–293. 152 indexed citations
6.
Ogonda, Luke, et al.. (2004). Delayed union and non-union of the ulna following intramedullary nailing in children. Journal of Pediatric Orthopaedics B. 13(5). 330–333. 40 indexed citations
7.
Wierzbicki, Anthony S., Dimitri P. Mikhailidis, Richard Wray, et al.. (2003). Statin-fibrate combination therapy for hyperlipidaemia: a review. Current Medical Research and Opinion. 19(3). 155–168. 122 indexed citations
8.
McIntyre, Hugh, et al.. (2002). Across the interface: the Hastings Heart Function Clinic. Heart. 88(suppl 2). ii23–ii27. 3 indexed citations
9.
Wierzbicki, Anthony S., Dimitri P. Mikhailidis, & Richard Wray. (2001). Drug Treatment of Combined Hyperlipidemia. American Journal of Cardiovascular Drugs. 1(5). 327–336. 22 indexed citations
10.
Crook, Martin, et al.. (2000). A paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate. Journal of Clinical Pathology. 53(10). 796–797. 8 indexed citations
11.
Marchant, B, et al.. (1989). Flumazenil causing convulsions and ventricular tachycardia.. BMJ. 299(6703). 860.2–860. 35 indexed citations
12.
Waller, D. G., et al.. (1989). Clinical efficacy of xamoterol, a /β1-adrenoceptor partial agonist, in mild to moderate heart failure. European Heart Journal. 10(11). 1003–1010. 21 indexed citations
13.
Wray, Richard, et al.. (1983). Comparative clinical trial of bemetizide/triamterene and cyclopenthiazide/potassium chloride combinations in patients with mild to moderate hypertension. Current Medical Research and Opinion. 8(9). 665–674. 1 indexed citations
14.
Sainsbury, Robert S., T. J. White, & Richard Wray. (1981). ECHOCARDIOGRAPHY IN ELDERLY PATIENTS WITH SYSTOLIC MURMURS. Age and Ageing. 10(4). 225–230. 2 indexed citations
15.
Wray, Richard. (1979). CRYOPROBE LEAKAGE OF NITROUS OXIDE INTO OPERATING ROOM AIR. Anesthesiology. 51(3). S336–S336. 12 indexed citations
16.
Wray, Richard, et al.. (1974). A correlative isotopic and histological study of soleal vein thrombosis. Journal of Clinical Pathology. 27(10). 813–816. 3 indexed citations
17.
Wray, Richard, B. Maurer, & John Shillingford. (1973). Prophylactic Anticoagulant Therapy in the Prevention of Calf-Vein Thrombosis after Myocardial Infarction. New England Journal of Medicine. 288(16). 815–817. 49 indexed citations
18.
Maurer, B., et al.. (1973). Lung shadows after acute myocardial infarction. Clinical Radiology. 24(3). 365–369. 3 indexed citations
19.
Millar, R. N. S., B. Maurer, D S Reid, et al.. (1973). Studies of intra-atrial conduction with bipolar atrial and His electrograms.. Heart. 35(6). 604–609. 10 indexed citations
20.
Wray, Richard, et al.. (1972). Propranolol-induced hypoglycaemia and myocardial infarction.. BMJ. 2(5813). 592.1–592. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Per‐Ola Attman Breakdown of academic impact, for papers by Irena Keber Breakdown of academic impact, for papers by Tomasz Fabiszak Breakdown of academic impact, for papers by Gerd Assmann Breakdown of academic impact, for papers by Susan R. Heckbert Breakdown of academic impact, for papers by Gursharan Dogra Breakdown of academic impact, for papers by Aldona Kubica Breakdown of academic impact, for papers by Robert Clarke Breakdown of academic impact, for papers by H Wilkes Breakdown of academic impact, for papers by Chen Shapira
Rankless by CCL
2026